A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Trial Profile

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms PIONEER6
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 19 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 28 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
    • 28 Oct 2016 Planned initiation date changed from 1 Oct 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top